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Niemann-Pick type C disease (NPC) is a rare and incurable neurological disorder that affects one in 120,000 people worldwide. Presently, there are no therapies approved by the U.S. Food and 
Drug Administration to treat NPC.
But Dr. Charles Vite, associate professor in neurology 
and neurosurgery in the Department of Clinical Studies at 
Penn Vet, is hopeful that this will soon change. In January, 
a clinical trial began at the National Institutes of Health to 
test a potential drug called cyclodextrin to treat NPC in 
children. Research by Dr. Vite paved the way for this Phase 
I trial, which offers hope for helping both humans and 
animals who suffer from NPC.
The disease is caused by the accumulation of excessive 
amounts of cholesterol and glycosphingolipids in the brain 
and other organs. Affected children are born clinically normal 
and then experience progressive ataxia, swallowing problems, 
seizures and impairment of motor and intellectual function in 
early childhood, and usually die in adolescence.
NPC also occurs naturally in animals. Cats, normal 
at birth, develop progressive ataxia and impaired motor 
function, with death occurring by six months of age due to 
the neurological disease.
The collaborations that led to this clinical trial began in 
2006, when Dr. Forbes Porter began a natural history study 
at the NIH to identify clinical and biochemical disease 
progression in patients with this rare disease. 
At about the same time, researchers at the University of 
Arizona and the University of California, San Francisco 
discovered a disease modifying drug, 2-hydroxypropyl-beta-
cyclodextrin (HPBCD). HPBCD is used to increase the 
solubility and dissolution rate of poorly water-soluble drugs. 
While the FDA considers it a safe, inactive pharmaceutical 
ingredient, it is not approved and marketed as an active 
pharmaceutical. 
Further studies performed in the mouse at the Albert 
Einstein School of Medicine and at the University of 
Texas Southwestern Medical Center identified HPBCD as 
effective in treating NPC. Studies in affected cats at Penn 
Vet identified that administration of the drug intrathecally 
(into the spinal fluid around the brain) resulted in the most 
effective therapy of Central Nervous System disease.
“Cats with NPC treated with intrathecal HPBCD are 
alive and well at over two years of age,” Dr. Vite said. “It 
works wonderfully.”
Based on the exciting discovery in animals, the 
Therapeutics for Rare and Neglected Diseases program in 
NIH’s National Center for Advancing Translational Sciences 
facilitated collaboration to advance research on cyclodextrin. 
Dr. Vite teamed with researchers from NIH, Washington 
University in St. Louis, Janssen Resarch and Development of 
Johnson & Johnson, and others to fine tune the therapy.
Penn Vet researchers discovered an effective route of 
drug delivery for NPC, allowing cyclodextrin to reach the 
nervous system through the spinal fluid. The NIH clinical 
trial, headed by Dr. Porter, is now using this method to 
deliver cyclodextrins to children with this disease.
“It doesn’t get any better than finding something that 
treats animals and then will go on to treat kids,” Dr. Vite said. 
The formation of a scientific collaboration involving 
academic, industry, government, and nonprofit patient 
advocacy organizations allowed the successful translation of 
HPBCD from the laboratory setting to a Phase I clinical 
trial in a rare disease in a relatively short period of time. If 
safety is demonstrated, the Phase II trial will follow. 
“I feel very thankful to be a part of this collaborative 
effort,” says Dr. Vite.
For a list of research supporters, visit www.vet.upenn.edu. 
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Mutations in either the NPC1 or NPC2 gene result in NPC with 
NPC1 mutations accounting for 95% of the cases and responsible 
for the disease in cats.  Kwon et al (2009) Cell 137: 1213-1224
